Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Canaccord Genuity analyst Edward Nash maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and lowers the price target from $153 to $149.
Canaccord Genuity analyst Edward Nash maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and lowers the price target from $153 to $149.
